S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Can't believe it's happening again (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The "Smart Money" Is Ready for May 1st Are You? (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
Free Trial
ASX:CU6

Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free CU6 Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

CU6 Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive CU6 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:CU6
CUSIP
N/A
CIK
N/A
Web
www.claritypharmaceuticals.com
Phone
61 2 9209 4037
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,560,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-45.33%
Return on Assets
-27.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.76
Quick Ratio
13.19

Sales & Book Value

Annual Sales
$9.49 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.20 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
306,350,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.28
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Alan John Taylor Ph.D.
    Executive Chairman
  • Dr. Colin David Biggin Ph.D.
    MD, CEO & Executive Director
  • Mr. David K. Green BEc.
    CA, Chief Financial Officer
  • Mr. Shaemus Gleason
    Executive Vice President of Operations
  • Dr. Matthew Harris BSc.
    M.B.A., Ph.D., CTO & Director of Technology
  • Dr. Jeffrey Norenberg
    Chief Scientific Officer
  • Michelle Parker
    Executive Vice President of Global Clinical Operations
  • Mr. Robert Vickery
    Company Secretary

Key Competitors

View All Competitors

Insiders


This page (ASX:CU6) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Can't believe it's happening again
Manward Press
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How to Know Which AI Company to Invest In… and When
Banyan Hill Publishing
Options trading has suddenly become more reliable.
Eagle Publishing
The Greatest Bull Market in Crypto History…
Weiss Ratings